Current Immunotherapies for Sarcoma: Clinical Trials and Rationale.
Current Immunotherapies for Sarcoma: Clinical Trials and Rationale.
复制标题
作者：
Mitsis D;Francescutti V;Skitzki J
肉瘤肿瘤罕见且异质，但它们具有许多可能促进免疫治疗反应的特征。包括疫苗在内的主动策略和涉及细胞过继免疫治疗的被动策略均已应用于临床。这些临床试验的结果表明，对特定患者有明显的益处。免疫检查点抑制的最新突破正在迅速应用于包括肉瘤在内的多种肿瘤类型。预计这些新兴的免疫疗法将对多种肉瘤表现出临床疗效。针对肉瘤患者定制免疫疗法的能力不断增强，无疑将激发人们对这种治疗方式的进一步热情和临床研究。
Sarcoma tumors are rare and heterogeneous, yet they possess many characteristics that may facilitate immunotherapeutic responses. Both active strategies including vaccines and passive strategies involving cellular adoptive immunotherapy have been applied clinically. Results of these clinical trials indicate a distinct benefit for select patients. The recent breakthrough of immunologic checkpoint inhibition is being rapidly introduced to a variety of tumor types including sarcoma. It is anticipated that these emerging immunotherapies will exhibit clinical efficacy for a variety of sarcomas. The increasing ability to tailor immunologic therapies to sarcoma patients will undoubtedly generate further enthusiasm and clinical research for this treatment modality.